Consequently, for those with HER2-negative GC who exhibit PD-L1 expression with CPS ≥ 5, the administration of nivolumab in combination with chemotherapy based on fluoropyrimidine and oxaliplatin is proposed as the first-line treatment option [88]. This evidence concerns the gene ERBB2 and gastric cancer.